The EU Pharma Package overhauls how medicines are sold and supplied, mandating denser contracts among manufacturers, distributors, hospitals, and public entities with new information-sharing, risk management, stock maintenance, and contingency requirements.

It redefines market logic to boost competition and responsibility across the lifecycle, from market authorization to regulatory protection, generics entry, and shortage management.

There are concerns that a heavier contractual burden could curb competition, raise costs, deter smaller players, and trigger tougher sanctions with scrutiny of liability, indemnities, audits, performance, and termination terms.

Antimicrobial policy blends public health, environmental safeguards, and economic incentives, including environmental risk assessments and a transferable exclusivity voucher for priority antibiotics to spur development.

Administrative simplification accelerates electronic submissions for market approvals, eliminates routine renewals for authorizations, and expands testing environments for innovative therapies.

An expanded environmental dimension requires comprehensive risk assessments and measures to cut environmental, production, usage, and disposal impacts, including water and soil contamination concerns.

Distributors must revise minimum volume, exclusive territory, allocation, and parallel export clauses to align with stronger supply-security goals in public tenders.

Continuity of supply becomes a central contractual obligation with explicit stock targets, failure alerts, contingency plans, alternative sourcing, and cooperation with authorities.

The Bolar exemption is broadened to allow generics and biosimilars to prepare market entry steps before patent expiry for immediate launch after protection ends.

The package aims to balance innovation incentives with faster patient access, rewarding innovators while increasing competition post-protection and prioritizing medicines addressing high clinical needs.

In Portugal, state-led procurement could raise costs but improve supply security through redundancy, stock management, and supplier diversification, with implications for transfer of authorizations and Bolar exemptions for generics and biosimilars.

Data protection remains eight years, but market protection shortens from two to one year and could extend to three years for drugs meeting unmet needs or with regulatory milestones, capping at 11 years of protection.